• Estrogen–ERα/KRT19 Signaling in Papillary Thyroid Cancer

  2026-08-14

  This study integrates public transcriptomic analysis, Oxford Nanopore sequencing, cell perturbation experiments, and xenograft validation to examine how estrogen promotes papillary thyroid carcinoma. Its central finding is that estrogen receptor α activation engages KRT19 to support tumor-cell proliferation, migration, and invasion, while also highlighting important limits in translating this axis to patients.

• tFUS, Nespas/miR-383-3p, and SHP2 After Stroke

  2026-08-14

  The reference study identifies a mechanistic link between low-intensity transcranial focused ultrasound and suppression of NLRP3-driven neuroinflammation after ischemic stroke. Its rat and microglial-cell experiments place the Nespas/miR-383-3p/SHP2 axis between neuromodulation and inflammasome regulation, providing a framework for testing SHP2-dependent microglial responses.

• Plerixafor (AMD3100): CXCR4 Workflow Guide

  2026-08-13

  Plerixafor (AMD3100) provides a reversible way to interrogate CXCL12/CXCR4 signaling in tumor trafficking, stem cell release, and inflammatory cell movement. This practical guide connects concentration-controlled assays with the reference study’s platelet-extravasation findings, emphasizing workflow design, controls, and troubleshooting.

• Chlorambucil: In Vitro Assay Workflows

  2026-08-13

  Chlorambucil is a practical DNA crosslinking model for separating growth arrest from true cell killing in cancer research. This workflow combines solvent control, time-resolved viability measurements, and orthogonal apoptosis assessment for more interpretable CLL, glioma, endothelial, and developmental cell studies.

• Recombinant Human FGF-19 Assay Workflows

  2026-08-12

  Build cleaner FGFR4/β-Klotho signaling experiments with a tag-free, E. coli-expressed ligand and orthogonal binding, proliferation, and metabolic readouts. This guide connects practical FGF-19 workflow design with time-resolved stress-signaling assays inspired by recent renal pyroptosis research, while clearly separating validated applications from exploratory extensions.

• Ranolazine Workflows for Cardiac Ischemia Research

  2026-08-12

  Ranolazine supports experimentally distinct studies of late sodium current, myocardial relaxation, and metabolic substrate use. This guide translates its anti-ischemic action into practical cardiac and hepatic workflows while clearly separating established product information, assay recommendations, and cross-domain hypotheses.

• Recombinant Annexin V for Apoptosis Detection

  2026-08-11

  The reference study established a practical bacterial-expression and purification workflow for soluble, polyhistidine-tagged Annexin V, then adapted the protein for FITC labeling and apoptotic-cell analysis. Its main contribution is methodological: it connects scalable recombinant production with flow-cytometric and fluorescence-microscopy detection of phosphatidylserine externalization.

• XPO1 Inhibition Combinations in Basal-Like TNBC

  2026-08-11

  This preclinical study used high-throughput drug screening, combination testing, patient-derived xenografts, and transcriptomic analyses to identify XPO1 inhibition as a rational strategy in basal-like triple-negative breast cancer. The strongest in vivo result came from combining KPT-330 with the PI3K/mTOR inhibitor GSK2126458, while XPO1 expression was linked to proliferative and metastatic features.

• LY2109761: From Smad Signals to Assay Design

  2026-08-10

  LY2109761 is a TGF-β receptor type I and II dual inhibitor that connects receptor kinase blockade with Smad signaling, cell-cycle control, and preclinical cancer and fibrosis models. This article translates the miR-424/503–CDC25A findings into practical assay strategies and interpretation safeguards.

• Sodium Nitroprusside for Vascular Research

  2026-08-09

  Use Sodium Nitroprusside as a controlled nitric oxide donor to separate vascular smooth muscle responsiveness from upstream endothelial and systemic effects. This guide connects practical vessel-ring and platelet workflows with the sex-specific hypertension findings of Xue et al., including troubleshooting strategies for fresh solutions, solvent controls, and variable tissue responses.

• Moxifloxacin Workflows for Toxicity Research

  2026-08-08

  Moxifloxacin supports a unified workflow spanning bacterial DNA gyrase studies, retinal ganglion cell viability assays, and antibiotic-associated metabolic research. This guide connects concentration control, mechanism-aware assay design, and troubleshooting so researchers can distinguish antibacterial activity from mammalian cytotoxicity or systemic response.

• AZD8055: Practical mTOR Inhibitor Guide

  2026-08-07

  AZD8055 is a selective ATP-competitive mTOR inhibitor for mechanistic studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and related metabolic responses. It is suited to preclinical cellular and animal workflows, but its poor aqueous solubility and limited clinical benefit make it unsuitable for studies requiring water-based formulation or clinical efficacy conclusions.

• Evaluating Fumagillin’s Efficacy Against Azumiobodo hoyamush

  2026-08-07

  This study systematically assessed the in vitro and in vivo effects of 20 antiprotozoal agents, including Fumagillin, on Azumiobodo hoyamushi—the pathogen responsible for soft tunic syndrome in edible ascidians. The findings clarify Fumagillin’s moderate antiparasitic activity and inform evidence-based aquatic disease management strategies.

• GANT61 Induces Apoptosis in ALK+ ALCL via Hh–PIK3IP1–Akt Mod

  2026-08-06

  This study demonstrates that GANT61, a direct Gli1/2 inhibitor, suppresses ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) cell growth and induces apoptosis by modulating the Hedgehog (Hh)–PIK3IP1–Akt signaling axis. The findings reveal mechanistic crosstalk between Hh and PI3K/Akt pathways, highlighting new avenues for targeted therapy and apoptosis detection strategies in hematologic malignancies.

• Targeting PLPP1 to Overcome Cisplatin Resistance in Lung Can

  2026-08-06

  The reference study reveals that combining Z-ligustilide with cisplatin impairs cisplatin resistance in lung cancer by modulating PLPP1-mediated phospholipid synthesis. This mechanistic insight may inform the development of new strategies against chemoresistant tumors and highlights the importance of integrated transcriptomic and metabolomic analyses in oncology research.

552 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page